To print: Select File and then Print from your browser's menu --------------------------------------------------------------------------------------- Title: Europe Approves Myocet (Liposome Encapsulated Doxorubicin Citrate) For Breast Cancer URL: http://www.pslgroup.com/dg/1DB7C6.htm Doctor's Guide August 1, 2000
DUBLIN, IRELAND -- August 1, 2000 -- Elan Corporation, plc ("Elan") announced that it has received community marketing authorization from the European Commission for Myocet™ (liposome encapsulated doxorubicin citrate complex) in combination with cyclophosphamide for first line treatment of metastatic breast cancer. Doxorubicin is an anthracycline glycoside that has application as an antineoplastic agent and is commonly used with other cancer drugs to treat patients with advanced stage or metastatic breast cancer. Doxorubicin can cause debilitating side effects such as severe nausea and vomiting, ulcers of the lining of the esophagus and intestines, bone marrow suppression, and most importantly, irreversible damage to the heart, sometimes resulting in congestive heart failure. Myocet is a proprietary liposomal formulation of doxorubicin designed to enhance delivery of the drug to tumor cells and reduce side effects while maintaining equivalent anti-tumor efficacy. Donal J. Geaney, chairman and chief executive of Elan, said, "We are excited that Myocet has been granted marketing authorization in Europe as the product will represent a significant new treatment opportunity for women who suffer from metastatic breast cancer. Our next step is to gain pricing approval and thereafter introduce Myocet into the major European markets through our established European salesforces." Related Link: Elan Corporation, plc. --------------------------------------------------------------------------------------------- Copyright © 1999 P\S\L Consulting Group Inc. All rights reserved. Republication or redistribution of P\S\L content is expressly prohibited without the prior written consent of P\S\L. P\S\L shall not be liable for any errors, omissions or delays in this content or any other content on its sites, newsletters or other publications, nor for any decisions or actions taken in reliance on such content. --------------------------------------------------------------------------------------------- This news story was printed from *Doctor's Guide to the Internet* located at http://www.docguide.com --------------------------------------------------------------------------------------- Return to News Story Page This site is maintained by webmaster@pslgroup.com Please contact us with any comments, problems or bugs. All contents Copyright (c) 1998 P\S\L Consulting Group Inc. All rights reserved.